LENZ Stock Overview
A biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
LENZ Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.28 |
| 52 Week High | US$38.93 |
| 52 Week Low | US$14.42 |
| Beta | 0 |
| 1 Month Change | -4.02% |
| 3 Month Change | -27.92% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 56.05% |
Recent News & Updates
Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth
Jan 01
LENZ Therapeutics: Time For A Pause
Nov 27LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
Aug 30Shareholder Returns
| LENZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.0% | 1.3% | 0.2% |
| 1Y | n/a | 0.9% | 22.0% |
Return vs Industry: Insufficient data to determine how LENZ performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how LENZ performed against the US Market.
Price Volatility
| LENZ volatility | |
|---|---|
| LENZ Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LENZ has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LENZ's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Eef Schimmelpennink | www.lenz-tx.com |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
LENZ Therapeutics, Inc. Fundamentals Summary
| LENZ fundamental statistics | |
|---|---|
| Market cap | US$734.00m |
| Earnings (TTM) | -US$60.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.4x
P/E RatioIs LENZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LENZ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$60.81m |
| Earnings | -US$60.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LENZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 22:46 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LENZ Therapeutics, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Matthew Caufield | H.C. Wainwright & Co. |